Nanoviricides (NNVC) Interest Coverage Ratio (2013 - 2024)
Nanoviricides' (NNVC) quarterly Interest Coverage Ratio came in at 13819.13 in Q4 2024, down 8322.07% year-over-year from 168.07 in Q1 2024, and down 8322.07% quarter-over-quarter from 164.08 in Q4 2023.
Powered by 
Analysis
Nanoviricides (NNVC) Interest Coverage Ratio (2013 - 2024) Analysis & Trends
Nanoviricides has disclosed Interest Coverage Ratio across 12 years of filings, most recently posting 13819.13 for Q4 2024.
- In Q4 2024, Interest Coverage Ratio fell 8322.07% year-over-year to 13819.13; the TTM figure through Jun 2025 stood at 64373.45 (down 37549.96% YoY), while the FY2025 annual figure was 64373.46, down 37549.97% from the prior year.
- Interest Coverage Ratio came in at 13819.13 for Q4 2024 at Nanoviricides, down from 164.08 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 1933.96 in Q2 2022 to a low of 19510.57 in Q4 2022.
- Average Interest Coverage Ratio over 5 years is 2592.19, with a median of 261.44 recorded in 2021.
- Year-over-year, Interest Coverage Ratio soared 839.73% in 2022 and tumbled 8322.07% in 2024.
- Over 5 years, Interest Coverage Ratio stood at 61.46 in 2020, then slumped by 1087.79% to 729.98 in 2021, then plunged by 2572.76% to 19510.57 in 2022, then soared by 99.16% to 164.08 in 2023, then plunged by 8322.07% to 13819.13 in 2024.
- Per Business Quant data, the three most recent Interest Coverage Ratio figures were 13819.13 in Q4 2024, 164.08 in Q4 2023, and 55.67 in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Nanoviricides | 22.04 Mn | 18.83 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -13,819.13 |
| Dec 31, 2023 | -164.08 |
| Sep 30, 2023 | -55.67 |
| Dec 31, 2022 | -19,510.57 |
| Sep 30, 2022 | -1,922.23 |
| Jun 30, 2022 | 1,933.96 |
| Mar 31, 2022 | -373.33 |
| Dec 31, 2021 | -729.98 |
| Sep 30, 2021 | -2,931.95 |
| Jun 30, 2021 | -261.44 |
| Mar 31, 2021 | -837.65 |
| Dec 31, 2020 | -61.46 |
| Sep 30, 2020 | -51.71 |
| Jun 30, 2020 | -41.07 |
| Mar 31, 2020 | -56.58 |
| Dec 31, 2019 | -395.65 |
| Jun 30, 2018 | -7.25 |
| Dec 31, 2017 | -39.71 |
| Sep 30, 2017 | -17.84 |
| Jun 30, 2017 | -17.98 |